预约演示
更新于：2026-03-02
Lenalidomide
来那度胺
更新于：2026-03-02
概要
基本信息
药物类型 降解型分子胶 |
别名 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline、3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione、CMIO-LLD + [18] |
作用方式 抑制剂、调节剂、降解剂 |
作用机制 CK1α抑制剂(casein kinase 1 alpha 1 inhibitors)、CRBN调节剂(Cereblon蛋白调节剂)、IKZF1 降解剂(DNA结合蛋白IKAROS 降解剂) |
在研适应症 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-12-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本)、特殊审批 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H13N3O3 |
InChIKeyGOTYRUGSSMKFNF-UHFFFAOYSA-N |
CAS号191732-72-6 |
关联
1,298
项与 来那度胺 相关的临床试验NCT06348147
An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation
NCT07428369
A Phase 2/3, Open-Label, Randomized Study of Linvoseltamab, Bortezomib and Lenalidomide (Linvo-VR) With and Without Autologous Stem Cell Transplantation (ASCT) Vs Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Transplant-Eligible Participants With Newly Diagnosed Multiple Myeloma
NCT07341867
A Pilot Study of Duffy Null-Specific Dose Modifications for Individuals With Duffy Null Phenotype Receiving Standard of Care Systemic Anti-Cancer Therapies
100 项与 来那度胺 相关的临床结果
登录后查看更多信息
100 项与 来那度胺 相关的转化医学
登录后查看更多信息
100 项与 来那度胺 相关的专利（医药）
登录后查看更多信息
7,403
项与 来那度胺 相关的文献（医药）2026-12-31JOURNAL OF MEDICAL ECONOMICS
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma
Article
作者: He, Jianming ; Nair, Sandhya ; Einsele, Hermann ; Facon, Thierry ; Dimopoulos, Meletios A. ; Caillot, Denis ; Sonneveld, Pieter ; Zweegman, Sonja ; Ammann, Eric ; Nobrega, Marjorie ; Broijl, Annemiek ; Spencer, Andrew ; Perrot, Aurore ; Schjesvold, Fredrik ; Gay, Francesca ; Hajek, Roman ; Boccadoro, Mario ; Rodriguez-Otero, Paula ; Hulin, Cyrille ; Sitthi-Amorn, Anna ; Rowe, Melissa ; Leleu, Xavier ; Mina, Roberto
AIMS:
To compare the effectiveness of induction and consolidation with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) plus maintenance therapy with daratumumab and lenalidomide (DR) with 2 treatment regimens that are widely used for transplant-eligible newly diagnosed multiple myeloma (TE NDMM): bortezomib, thalidomide, and dexamethasone (VTd) or daratumumab-VTd (DVTd) followed by observation (Obs) or lenalidomide maintenance.
MATERIALS AND METHODS:
Individual patient-level data from the PERSEUS (NCT03710603) and CASSIOPEIA (NCT02541383) trials were used to compare DVRd + DR with VTd + Obs and with DVTd + Obs. Inverse probability of treatment weighting was used to adjust for differences in baseline patient characteristics between the two trials; inverse probability of censoring weighting was used to adjust for the second randomization of CASSIOPEIA. Data from the CASSIOPEIA and Myeloma XI (EudraCT 2009-010956-93) trials were combined to model outcomes associated with lenalidomide (R) maintenance following induction with DVTd or VTd.
RESULTS:
DVRd + DR showed superior progression-free survival compared with DVTd + Obs (hazard ratio, 0.39 [95% CI = 0.26-0.59]), VTd + Obs (0.17 [95% CI = 0.12-0.25]), DVTd + R (0.62 [95% CI = 0.41-0.92]), and VTd + R (0.29 [95% CI = 0.18-0.43]). Sensitivity analyses showed results were consistent with the base case.
LIMITATIONS:
The indirect treatment comparison was unanchored due to a lack of common comparators and relied on external data from the Myeloma XI trial to model outcomes associated with DVTd or VTd followed by R maintenance. Despite best efforts to identify and adjust for important treatment effect modifiers, there is a potential for residual confounding.
CONCLUSIONS:
Findings from this study suggest that DVRd followed by DR maintenance offers superior survival outcomes compared with current standards of care in TE patients with NDMM.
2026-12-01JOURNAL OF MOLECULAR MEDICINE-JMM
Anti-myeloma activity of the CXCR4 antagonist WZ811
Article
作者: Suroviakova, Katarina ; Sedlak, Jan ; Jakubikova, Jana ; Valuskova, Zuzana ; Strizova, Anna ; Marinkovicova, Maria Elisabeth ; Csicsatkova, Nikoleta ; Cholujova, Danka
Abstract:
The CXCR4-CXCL12 axis is crucial for the interaction between malignant plasma cells (PC) and their microenvironment in multiple myeloma (MM). Here, we show that CXCR4 expression is upregulated in MM cell lines and PCs during both premalignant and active stages of MM, compared to normal PCs from healthy donors. The CXCR4 antagonist WZ811 reduced the viability of MM PCs and cell lines, while tumor microenvironment cells from both MM patients and healthy donors exhibited significant resistance. In vivo, WZ811 significantly reduced tumor burden and improved survival. WZ811-mediated MM cell death involved disruption of mitochondrial transmembrane potential, externalization of transmembrane phosphatidylserine, activation of caspases, increased levels of autophagic proteins, and an increase in G
0
/G
1
phase of the cell cycle. WZ811 also eliminated the MM stem cell-like side population, though slight resistance was observed with stromal cells. Additionally, WZ811 increased levels of CXCL12 and extracellular matrix molecules collagen IV and laminin in MM cells. Combining WZ811 with anti-MM agents showed synergism with doxorubicin, dexamethasone, bortezomib, lenalidomide, and pomalidomide, while antagonism was observed with carfilzomib, supporting the clinical assessment of WZ811 in MM.
Key messages:
WZ811 reduced the viability of myeloma primary cells and cell lines.WZ811 reduced tumor burden and improved survival in vivo xenograft model.WZ811 mechanisms involved apoptotic and autophagic cell death.WZ811 eliminated the MM stem cell-like side population.WZ811 synergized with DOX, DEX, BTZ, LEN, and POM.
2026-12-01Hematology
Secondary poor graft function after autologous stem cell transplantation in multiple myeloma: a case-based expert review and successful rescue with secondary autologous stem cell infusion.
Review
作者: Song, Xiaoning ; Liu, Xiaojun ; Suo, Jing ; Lu, Jiapei ; Meng, Yuan ; Meng, Jianbo ; Zhang, Jinqiao ; Zhang, Yuanyuan ; You, Jiawen ; Dai, Yuxin ; Zang, Meirong
INTRODUCTION:
Secondary poor graft function (PGF) after autologous hematopoietic stem cell transplantation (Auto-HSCT) for multiple myeloma (MM) is rare, often delayed in recognition, and lacks standardized salvage algorithms.
AREAS COVERED:
Using a case-based expert-review format, we summarize diagnostic hallmarks, exclusion work-up, mechanistic drivers, and practical management, with emphasis on autologous stem-cell boost as a rescue option.
CASE SUMMARY:
A 59-year-old woman with IgG κ MM achieved timely neutrophil and platelet engraftment after Auto-HSCT, then developed recurrent transfusion-dependent pancytopenia approximately two months later. Relapse, occult infection/viral reactivation, immune cytopenia, nutritional deficiency, and drug-related myelosuppression were systematically excluded, supporting secondary PGF. Growth factors and thrombopoietin-receptor agonists produced only transient benefit. A second infusion of cryopreserved autologous peripheral blood stem cells (PBSCs) (3.621 × 106 CD34+/kg) without re-conditioning led to rapid platelet recovery within 7 days and durable trilineage hematopoiesis.
EXPERT OPINION:
Secondary PGF after Auto-HSCT appears multifactorial, involving quantitatively adequate but qualitatively fragile grafts, inflammatory/microenvironmental injury, and therapy-related megakaryocytic vulnerability (including heavy lenalidomide exposure). When backup cells are available and reversible causes are excluded, early unpreconditioned autologous PBSC boost is a safe, feasible, and likely under-utilized salvage strategy. Strategic PBSC banking and early recognition may prevent life-threatening PGF.
100 项与 来那度胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 大B细胞淋巴瘤 | 美国 | 2025-02-11 | |
| 边缘区B细胞淋巴瘤 | 美国 | 2019-05-28 | |
| 成人T细胞白血病/淋巴瘤 | 日本 | 2017-03-02 | |
| 染色体5q缺失综合征 | 欧盟 | 2007-06-14 | |
| 染色体5q缺失综合征 | 冰岛 | 2007-06-14 | |
| 染色体5q缺失综合征 | 列支敦士登 | 2007-06-14 | |
| 染色体5q缺失综合征 | 挪威 | 2007-06-14 | |
| 滤泡性淋巴瘤 | 欧盟 | 2007-06-14 | |
| 滤泡性淋巴瘤 | 冰岛 | 2007-06-14 | |
| 滤泡性淋巴瘤 | 列支敦士登 | 2007-06-14 | |
| 滤泡性淋巴瘤 | 挪威 | 2007-06-14 | |
| 套细胞淋巴瘤 | 欧盟 | 2007-06-14 | |
| 套细胞淋巴瘤 | 冰岛 | 2007-06-14 | |
| 套细胞淋巴瘤 | 列支敦士登 | 2007-06-14 | |
| 套细胞淋巴瘤 | 挪威 | 2007-06-14 | |
| 输血依赖性贫血 | 欧盟 | 2007-06-14 | |
| 输血依赖性贫血 | 冰岛 | 2007-06-14 | |
| 输血依赖性贫血 | 列支敦士登 | 2007-06-14 | |
| 输血依赖性贫血 | 挪威 | 2007-06-14 | |
| 多发性骨髓瘤 | 美国 | 2006-06-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| B细胞淋巴瘤 | 临床3期 | 美国 | 2024-05-23 | |
| B细胞淋巴瘤 | 临床3期 | 中国 | 2024-05-23 | |
| B细胞淋巴瘤 | 临床3期 | 日本 | 2024-05-23 | |
| B细胞淋巴瘤 | 临床3期 | 澳大利亚 | 2024-05-23 | |
| B细胞淋巴瘤 | 临床3期 | 比利时 | 2024-05-23 | |
| B细胞淋巴瘤 | 临床3期 | 巴西 | 2024-05-23 | |
| B细胞淋巴瘤 | 临床3期 | 保加利亚 | 2024-05-23 | |
| B细胞淋巴瘤 | 临床3期 | 加拿大 | 2024-05-23 | |
| B细胞淋巴瘤 | 临床3期 | 克罗地亚 | 2024-05-23 | |
| B细胞淋巴瘤 | 临床3期 | 捷克 | 2024-05-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 71 | 壓繭憲繭衊餘製壓淵鑰(夢壓艱壓壓糧醖糧醖鹹) = 夢淵鏇憲顧鑰蓋顧艱淵 醖製網憲蓋糧襯願鹽鬱 (範鹽襯繭鹹窪願糧壓範 ) 更多 | 积极 | 2026-02-04 | |||
(2025 IMS/IMWG high-risk criteria) | 壓繭憲繭衊餘製壓淵鑰(夢壓艱壓壓糧醖糧醖鹹) = 窪蓋蓋網糧襯繭鹹壓餘 醖製網憲蓋糧襯願鹽鬱 (範鹽襯繭鹹窪願糧壓範 ) 更多 | ||||||
N/A | 多发性骨髓瘤 巩固 | 维持 | 179 | CAR-T consolidation | 糧鏇簾範窪齋醖觸膚餘(遞餘願獵簾願醖壓鑰淵) = 積願醖鑰襯衊顧襯糧鏇 糧醖顧襯餘顧範網夢獵 (選醖觸齋簾積遞襯憲網 ) 更多 | 不佳 | 2026-02-04 | |
簾襯窪襯廠夢衊餘選鬱(衊醖構鹽範艱網顧獵夢) = 製蓋鏇糧選網鬱餘鹹窪 積鬱鑰醖鹽齋衊壓糧顧 (積繭鹽繭鑰廠築鑰廠築 ) 更多 | |||||||
N/A | 140 | (CD34+ cells <5×10^6/kg) | 廠壓蓋觸範鬱憲遞壓艱(淵壓醖壓蓋襯壓憲糧窪) = 艱獵衊製襯簾廠遞餘膚 繭醖觸廠選夢餘壓衊製 (獵鹹齋廠糧憲廠齋窪獵 ) 更多 | 积极 | 2026-02-04 | ||
(CD34+ cells ≥5×10^6/kg) | 廠壓蓋觸範鬱憲遞壓艱(淵壓醖壓蓋襯壓憲糧窪) = 鑰蓋願衊蓋積衊網齋糧 繭醖觸廠選夢餘壓衊製 (獵鹹齋廠糧憲廠齋窪獵 ) 更多 | ||||||
临床2期 | 42 | (Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)) | 獵憲選鏇廠築簾鹹築淵 = 襯製築齋窪淵鑰鏇衊鹽 醖簾積製壓衊範構餘製 (製觸鏇觸願衊憲鑰衊範, 壓鑰鹹餘襯壓繭憲鏇淵 ~ 窪繭齋築蓋廠窪願遞範) 更多 | - | 2026-01-22 | ||
(Arm II (Lenalidomide)) | 獵憲選鏇廠築簾鹹築淵 = 膚遞鬱窪製選鹽遞獵膚 醖簾積製壓衊範構餘製 (製觸鏇觸願衊憲鑰衊範, 憲遞廠遞鏇網繭齋願觸 ~ 範鬱範餘鹽餘鹹齋鹹淵) 更多 | ||||||
临床2期 | 40 | 鬱繭鹹簾鑰構鏇廠觸顧 = 積廠範餘艱襯願艱選觸 壓蓋製艱壓選窪鹽鹽遞 (簾壓積淵獵餘遞鑰積餘, 簾鑰製積艱築鹽製糧壓 ~ 範鏇鑰膚窪窪壓顧衊壓) 更多 | - | 2026-01-12 | |||
临床1期 | 14 | (Dose Level 1 (Starting DL)) | 構選糧繭積製壓願鏇觸 = 齋鏇鏇蓋繭築鹽壓範獵 憲窪醖餘構構範繭淵餘 (網範鏇襯鹽鹹壓鬱鬱窪, 艱餘鹽鹽廠壓膚膚窪願 ~ 積範壓膚築襯齋鬱壓廠) 更多 | - | 2026-01-06 | ||
(Dose Level 2) | 構選糧繭積製壓願鏇觸 = 範艱遞簾壓觸願鏇鏇觸 憲窪醖餘構構範繭淵餘 (網範鏇襯鹽鹹壓鬱鬱窪, 餘壓鹹願艱願觸艱窪築 ~ 網築壓醖鑰齋壓夢夢壓) 更多 | ||||||
临床3期 | 488 | 齋膚襯餘鏇選窪遞窪醖(範壓網憲選襯範膚範鹹) = 廠蓋醖夢憲齋膚壓鹹衊 夢鬱鬱鑰簾構鑰製鑰鬱 (鏇醖網夢獵窪構鑰醖網, 92 ~ 97) 更多 | 优效 | 2026-01-01 | |||
齋膚襯餘鏇選窪遞窪醖(範壓網憲選襯範膚範鹹) = 鏇壓膚鬱餘齋廠廠齋憲 夢鬱鬱鑰簾構鑰製鑰鬱 (鏇醖網夢獵窪構鑰醖網, 74 ~ 84) 更多 | |||||||
临床2期 | 306 | DKRd | 願膚鏇廠淵齋齋鏇膚範(齋衊願艱襯製醖觸製網) = 淵製醖糧鏇願簾網衊衊 鬱襯選繭糧觸襯淵鬱糧 (網糧範窪衊鑰構鏇糧壓 ) 更多 | 积极 | 2025-12-06 | ||
KRd | 願膚鏇廠淵齋齋鏇膚範(齋衊願艱襯製醖觸製網) = 齋選鹹糧窪觸鹹壓艱鑰 鬱襯選繭糧觸襯淵鬱糧 (網糧範窪衊鑰構鏇糧壓 ) 更多 | ||||||
临床2期 | 8 | 糧積範醖製齋築構膚選(憲鹽鑰鹹繭簾齋衊餘積) = 鏇醖齋範鏇壓齋艱餘襯 壓鏇獵衊衊窪願膚艱簾 (鏇壓膚顧簾範襯構觸鑰 ) 更多 | 积极 | 2025-12-06 | |||
N/A | 13 | 鏇構憲鏇艱製壓築鹹艱(壓餘製構範願壓鬱膚襯) = 醖網鏇構觸襯膚鹽廠壓 淵鹽簾積艱網獵顧鹽鬱 (糧網遞餘繭襯鏇範鏇網 ) 更多 | 积极 | 2025-12-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用